58 results about "ABCA1" patented technology

The present invention relates to an in vitro method for diagnosing a genetic predisposition or susceptibility for a cardiovascular disease, condition or disorder in a mammal which comprises detecting of at least three particular single nucleotide polymorphisms (SNP) in a sample obtained from said mammal in at least one of a genomic locus-derived nucleic acid or fragment thereof of the loci APOB, APOE, ABCA1, CETP, LCAT, LIPC, LPL, LDLR, APOC2, APOA5, APOA4, APOC3, and APOA1. Furthermore, the present invention relates to the improved diagnosis that is based on the analysis of several haplotypes for the above-mentioned loci (i.e. a combination of said haplotypes).

A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed.

Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.

A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and / or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula:wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g., a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, and an N-substituted carbamoyl group), the groups R2a and R2b may bond together to form a hydrocarbon ring with an adjacent carbon atom, provided that compounds in which all of the groups R1a, R1b, R1c and R1d are t-butyl groups, and both of the groups R2a and R2b are hydrogen atoms or both of the groups R2a and R2b are methyl groups are excluded; or a pharmacologically acceptable salt thereof.

The invention features methods for treating, preventing or modulating a neurological disease or disorder, or for modulating an anaesthetic or a fertility process by administering compounds that modulate ABCA1 expression or activity. The invention also features methods for identifying compounds useful for such methods.

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.

A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and / or a deleterious lipoprotein profile in an individual.

The invention relates to the application of isoflavones red clover (form 1) and genistein (form 2). The invention is utilized for the preparation of medicine through strengthening the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis. The medicine of strengthing the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis comprises the medicine presented the liveness through the up-regulation of the high density lipoprotein receptor CLA-1 / SR-BI and the ATP cassette antigen ABCA1. The invention also relates to the drug composition of strengthening the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis, the active constituents efficient chosen from the isoflavones red clover (form 1) and genistein (form 2) provided on the drug composition and optional carrier which is able to be adopted by the pharmacy.

The present invention relates to a cell culture system to provide a tool for assessing the potential of a patient's serum for preventing the accumulation of cholesterol in arteries (i.e. serum efflux potential) that leads to atherosclerosis and to screen new drug compositions being developed to reduce the accumulation of cholesterol or enhance the clearance of cholesterol from the vessel wall. The present invention combines two individual assays, which are two different cholesterol assays: an assay measuring scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux and an assay measuring ATP binding cassette protein 1 (ABCA1)-mediated cholesterol efflux, and uses them in parallel to test human and animal sera for their potential to stimulate efflux, as mediated by either of the two receptors described above.

The invention discloses 2-acylamino-3-alkoxyl substituted pyridine compounds and an application of the compounds in treatment and / or prevention of atherosclerosis-induced cardiovascular diseases. Experiments verify that the compounds or pharmaceutical compositions have the function of up-regulating or stabilizing ABCA1 and SR-BI / CLA-1 and can be used for inhibiting bubblization of macrophage or enhancing cholesterol efflux of macrophage. Experiments show that the compounds have the effects of reducing blood fat and cholesterol and have an application prospect of becoming a medicine for reducing blood fat, treating atherosclerosis, cardiovascular diseases and the like.

The invention relates to tetrahydroindoloquinazoline compounds and application thereof. Structures of the compounds are shown as a general formula (I) shown in the specification. The compounds are used for (1) preparing medicines for treating cardiovascular and cerebrovascular diseases; (2) preparing preparations for improving the expression of AMPK, ABCA1 and SR-BI; (3) preparing preparations foractivating the activity of a nuclear receptor NR, inhibiting the activity of NLRP3, the activity of IL-1[beta], the activity of NF-[kappa]B and the activity of MAPKs; (4) preparing preparations for promoting outflow of cell cholesterol; and (5) preparing anti-inflammatory medicines.

The invention provides a construction method for an exosome loading ABCA1 mRNA, belonging to the technical field of gene medicine. The method comprises constructing an ABCA1 fusion expression vector and a CD9 fusion expression vector, wherein the ABCA1 fusion expression vector is a CDS sequence of ABCA1 and a tandem RNA binding protein recognition sequence. The CD9 fusion expression vector is a CD9 CDS sequence and a corresponding RNA binding protein encoding gene, and the ABCA1 fusion expression vector and the CD9 fusion expression vector are co-transfected into the liver cells, and the exosomes are collected after the culture, so that the ABCA1 mRNA is excreted. body. The construction method can improve the efficiency of loading ABCA1 mRNA into exosomes, overcome the problem that the large molecular weight ABCA1 mRNA molecule cannot be efficiently loaded into the exosomes, and obtain a large amount of exosomes containing ABCA1 mRNA.

The invention discloses an agent box for detecting individual cholesterin metabolism unconventionality impressionable heredity risks. The agent box comprises specificity primer pair and specificity fluorescent detecting probe pair for detecting number rs2230806 SNP site on adenosine triphosphate bind box transferring body A1 gene (ABCA1), number rs693 SNP site on apolipoprotein B gene (APOB), number rs320 SNP site and rs285 SNP site on lipoproteins lipase gene (LPL), specificity primer pair and DNA sequencing primer for detecting number rs429358 SNP site and rs7412 SNP site on detection apolipoprotein E gene (APOE), fluorescent definite quantity PCR general component, PCR reaction component, PCR outcome yield cleanse component and DNA sequencing reaction component etc.. The agent box of the invention assesses individual cholesterin metabolism unconventionality impressionable heredity risks by detecting synchronously mononucleotide polymorphism site gene type on ABCA1, APOB, LPL and APOE genes correlative closely to individual cholesterin metabolism unconventionality impressionable heredity risks.

The invention relates to an aryl-substituted amide compound in the formula (I), a preparing method thereof, a medicine composition comprising the same, and application of the amide compound and the medicine composition to pharmacy, wherein Arl, L1, M1, M2, L2 and Ar2 are defined as in the text. The aryl-substituted amide compound can excite TRPV1 and nuclear receptors (LXRs, PPARs and RXR), adjust expression of cholesterol excretion gap-associated protein ABCA1 / G1, SR-BI, adjust expression of inflammation gap-associated protein TNF-alpha and the like, and play roles in promoting excretion of cholesterol and lipid, reducing sugar, adjusting blood lipid, resisting inflammation and reducing blood pressure, and can be used for treating and / or preventing and / or relieving cardiovascular and cerebrovascular diseases, adjusting blood lipid, and resisting atherosclerosis, diabetes mellitus, inflammation, pain and hypertension.

The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

The present invention discloses a reagent kit which detects the genetic susceptibility of the synthetic disease of adult woman. The reagent kit comprises a specific primer pair and a specific fluorescent probe pairs which simultaneously detects the SNP polymorphic genotype on the genes of CYBA, CAT, LPL, LEP, ADIPOQ, SOD3, IL3, NOS3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13, CBS, a routine component which is used for the fluorescent quantitative PCR testing and the like. The reagent kit of the invention evaluates the genetic susceptibility of the synthetic disease of adult woman through simultaneously detecting the mononucleotide polymorphism site genotype which is closely linked to the genetic susceptibility of the synthetic disease of adult woman.

The invention provides methods and compositions for determining whether an individual is at risk of developing, or has, one or more angiogenic disorders. The methods detect the presence and / or amount of one or more genes or gene products in a sample, including a RORA, CRIM1, CXCR4, C5orf26, IGHG3, NALP2, PLA2G4A, IGLJ3, SHQ1, UCHL1, TANC1, PKP2, DNAJC6, C6orf105, NALP1, RGS13, CXCL13, RPS6KA2, MMP7, IL1A, ABCA1, VCAN, KIAA0888, ENPP2, and FAM38B gene or gene product. In addition, the invention provides methods for using one or more of these genes or gene products as a target for preventing or delaying the onset of one or more angiogenic disorders or treating a patient with one or more such disorders. The angiogenic disorder can be, for example, an ocular angiogenic disorder, for example, a disorder associated with choroidal neovascularization, for example, age-related macular degeneration.

The present invention provides a kit for detecting genetic predisposition of adult male syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 48 SNP polymorphism genotypes on the genes LPL, TNF-alpha, LEP, ADIPOQ, SOD3, IL3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of adult male syndrome by detecting the genotypes of the 48 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of adult male syndrome.

The invention belongs to the field of biochemical engineering, and in particular relates to a chemical synthetic method of a low affinity ligand of an oxidized low density lipoprotein receptor CD36. The method comprises the following steps of: carrying out a chemical reaction on 4-Dimethylaminopyridine, N, N'-Dicyclohexylcarbodiimide, azelaic acid and 7-ketocholesterol; and obtaining oxLig-1 through extraction, sample mixing, packing, purification and collection. Experiments show that the chemically synthesized oxLig-1 has same physiological activity with that of oxLig-1 separated and purified from oxLDL (oxidized low density lipoprotein), and the oxLig-1 activates cell signaling mediated by CD36. According to the chemical synthetic method disclosed by the invention, oxLig-1 is synthesized by the chemical method, and oxLig-1 has a completely consistent chemical structure with that of the low affinity ligand of CD36 and can activate ERK (Extracellular Signal-Regulated Kinase) and JNK (Jun N-Terminal Kinase) and up-regulate expression of a cholesterol outflow gene, namely, a triphosadenine binding cassette transporter A1 (ABCA1).

The invention relates to the field of fermentation, particularly to a plant fermentation product and use thereof for regulating gene expression and cardiovascular care. The plant fermentation productis prepared by a method including steps of: subjecting a composition of cape jasmine and purslane to extraction with water to obtain a plant extract; subjecting the plant extract to fermentation withbrewer yeast, Lactobacillus plantarum and acetic acid bacteria in order to obtain the plant fermentation product. The invention further provides use of the plant fermentation product for regulating expression of CD36, ABCA1, PROC, VWF, F3, SERPINE1, PDGFC, FGF2, IGF2BP3, IGF1R, IL8, VCAM1 and CASP8 genes and for cardiovascular care.

The invention relates to an isolated antibody that binds to native ABCA1 polypeptide and its uses for the detection of ABCA1 polypeptides in tissue samples.

The invention discloses a kit used for detecting the genetic susceptibility of cardio-cerebral diseases. The kit comprises a specific primer pair which detects genotypes of eighteen sites of single nucleotide polymorphism (SNP) in ABCA1, ACE, ADIPOQ, AGT, APOB, APOE, AT1R, CYP11B2, ENOS, LEP, LPL, MTHFR, PON1, PPARG, SOD3, UCP2 and VDR simultaneously and specified fluorescent probe pairs, conventional components used in fluorescence quantitative PCR detecting, and the like. The kit of the invention evaluates genetic susceptibility of cardio-cerebral diseases by detecting genotypes of eighteen sites of single nucleotide polymorphism which is closely related to genetic susceptibility of cardio-cerebral diseases.